知镜 Cognispect · 医学文献与研究工作台

A blinded, non-inferiority randomised clinical trial comparing the efficacy and safety of low-dose methotrexate and ciclosporin for the control of moderate to severe canine atopic dermatitis.

Rostang A, Mosca M, Panzuti P, Pressanti C, Idée A, Buendia E, Germain PA, Cochet-Faivre N, Meyer L, Legain M, Geffré A, Brun J, Maache M, Berny P, Prouillac C, Cadiergues MC, Pin D.
Veterinary journal (London, England : 1997) · 2026-11-07 · PMID 42998873

文献摘要

Background Canine atopic dermatitis (cAD) is a chronic, inflammatory skin disease that may require long-term systemic immunomodulatory treatment. Low-dose methotrexate (MTX) is an inexpensive immunomodulator used in human dermatology, but robust veterinary data are lacking. Objective To determine whether weekly subcutaneous low-dose MTX is non-inferior to oral ciclosporin (CsA) in controlling moderate-to-severe cAD. Animals Fifty-five client-owned dogs with non-seasonal moderate-to-severe cAD enrolled at nine dermatology centres in France. Materials and methods Randomised, double-blind, positive-controlled, multicentre non-inferiority trial. Dogs received either subcutaneous MTX (0.15-0.5 mg/kg/week) plus oral placebo, or oral CsA (5 mg/kg/day, then spaced) plus injectable placebo. The primary endpoint was the percentage reduction in the CADESI-04 lesional score on week 28 (non-inferiority margin 20%). Secondary endpoints included the Pruritus Visual Analogue Scale (PVAS) and CADESI-04 scores, assessed 4-weekly, and drug protocol safety assessments. Results Fifty-five dogs were randomised (MTX n = 28; CsA n = 27). At week 28, mean CADESI-04 reductions were 65.4% (MTX) and 69.5% (CsA), demonstrating non-inferiority. CsA induced faster improvement (weeks 4-12), but efficacy converged by week 20. Gastrointestinal adverse events occurred more frequently with MTX (82%) than with CsA (70%). No consistent haematological, renal or hepatic injury was observed during the study. Two MTX-treated dogs developed severe liver disease during long-term follow-up. Clinical relevance Weekly subcutaneous low-dose MTX provided non-inferior control of lesions and pruritus compared with CsA by week 28. Although slower in onset and associated with more gastrointestinal adverse events, MTX may represent an affordable long-term cAD treatment option, with appropriate hepatic monitoring.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。